Overview

An Interaction Study of LY3200882 in Healthy Participants

Status:
Completed
Trial end date:
2019-02-23
Target enrollment:
Participant gender:
Summary
The main purpose of this study is to evaluate the effect of itraconazole on the amount of LY3200882 in the blood stream and how long the body takes to get rid of LY3200882. The safety and tolerability of LY3200882 when given with itraconazole will be evaluated. The study is expected to last up to 19 days from the first dose to follow-up (inclusive). Screening will occur up to 28 days prior to enrollment.
Phase:
Phase 1
Details
Lead Sponsor:
Eli Lilly and Company
Treatments:
Hydroxyitraconazole
Itraconazole